noom semaglutide microdose GLP-1rx — Low Dose GLP-1 Weight Loss Program Weight-loss company Noom pivots to

In addition to initial FLOW trial findings indicating Ozempic can offer kidney protective benefits, results of Novo Nordisks SELECT trial showed that semaglutide significantly reduced rates of kidney and cardiovascular events compared with placebo in participants with overweight and obesity with cardiovascular disease but without diabetes

The 11.0% of adults who are past GLP-1 users look almost nothing like the current-user segment younger, more diverse, over-indexing among Gen Z (18.1%), single parents (20.6%), Black Americans (16.9%), and LGBTQ+ adults (14.1%)

Here is what happened when I tried both

What about effectiveness